Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00467493 · ClinicalTrials.gov registry record · Phase 2
Partial Double-Blind, Placebo-Controlled Study to Assess the Effect of Anastrozole on the Endometrium in Healthy Volunteers
A Phase 2 study of Menstruation Disorders, sponsored by Meditrina Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
- 2
- Study locations
NCT00467493: Completed Phase 2 study of Menstruation Disorders, sponsored by Meditrina Pharmaceuticals.
NCT00467493 is a Phase 2 study of Menstruation Disorders that has completed, run by Meditrina Pharmaceuticals. The registered enrollment target is 64 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (52% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00467493, a Phase 2 study of Menstruation Disorders, has completed, sponsored by Meditrina Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
- 2
- Study locations
Study Summary
Aromatase inhibitors have been approved for use in postmenopausal women to treat and prevent breast cancer. They act by blocking the action of the enzyme, aromatase, that is necessary for the production of estradiol. This class of drugs, aromatase inhibitors, are very effective in reducing estradiol levels in postmenopausal women and in treating estrogen receptor positive breast cancers. This study is examining the effect of a specific inhibitor, anastrozole, on endometrial thickness in premenopausal women. The endometrium is sensitive to estradiol and also has local aromatase which, if inhibited, may result in reduced endometrial thickness. The main hypothesis is that anastrozole can be administered at any time during the menstrual cycle and reduce endometrial thickness compared to placebo.
Conditions Studied
Interventions
- DRUG Anastrozole
Study Locations (2)
Michigan
- Jasper Research Clinic - Kalamazoo
- University Women's Care - Southfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2007-03 |
| Est. Completion | 2007-09 |
| Phase | Phase 2 |
What the finished NCT00467493 record still lists
NCT00467493 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (52% lower).
The record links to 1 condition, with Menstruation Disorders appearing as the primary indexed condition, and to 1 intervention - of which Anastrozole is the first listed.
NCT00467493 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT00467493 about?
NCT00467493 is a clinical study titled "Partial Double-Blind, Placebo-Controlled Study to Assess the Effect of Anastrozole on the Endometrium in Healthy Volunteers". Aromatase inhibitors have been approved for use in postmenopausal women to treat and prevent breast cancer. They act by blocking the action of the enzyme, aromatase, that is necessary for the production of estradiol. This class of drugs, aromatase inhibitors, are very effective in reducing estradiol...
What is the current status of trial NCT00467493?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2007-03. Estimated completion is 2007-09.
What conditions does trial NCT00467493 study?
This clinical trial studies the following conditions: Menstruation Disorders.
What interventions are being tested in trial NCT00467493?
The interventions under investigation include: Anastrozole (DRUG).
Who is sponsoring clinical trial NCT00467493?
This trial is sponsored by Meditrina Pharmaceuticals, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00467493 being conducted?
This trial has 2 study locations across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00467493's enrollment target sits among peer trials
64 996th of 2000 higher than 992 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia